Severe congenital protein C deficiency: The use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications

Biologics: Targets and Therapy

Volumn 2, Issue 2, 2008, Pages 285-296

  Knoebl, Paul N ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coagulopathy; Deficiency; Protein C; Purpura fulminans; Replacement therapy

Indexed keywords

EID: 77954718811     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s1954     Document Type: Review

References (89)

1. Alhenc-Gelas M, Emmerich J, Gandrille S, et al. 1995. Protein C infusion in a patient with inherited protein C deficiency caused by two missense mutations: Arg 178 to Gln and Arg-1 to His. Blood Coagul Fibrinolysis, 6:35-41.
2. Allaart CF, Poort SR, Rosendaal FR et al. 1993. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet, 341:134-8.
3. Auberger K. 1992. Evaluation of a new protein-C concentrate and comparison of protein-C assays in a child with congenital protein-C deficiency. Ann Hematol, 64:146-51.
4. Baliga V, Thwaites R, Tillyer ML, et al. 1995. Homozygous protein C deficiency-manage ment with protein C concentrate. Eur J Pediatr, 154:534-8.
5. Barnes C, Newall F, Higgins S, et al. 2002. Perinatal management of patients at high risk of homozygous protein C deficiency. Thromb Haemost, 88:370-1.
6. Beckman RJ, Schmidt RJ, Santerre RF, et al. 1985. The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNA's. Nucl Acids Res, 13:5233.
7. Bertina RM, Broekmans AW, van der Linden IK, et al. 1982. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost, 48:1-5.
8. Bertina RM, Koeleman BPC, Koster T, et al. 1994. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369:64-7.
9. Bovill EG, Bauer KA, Dickerman JD, et al. 1989. The clinical-spectrum of heterozygous protein C deficiency in a large new England Kindred. Blood, 73:712-7.
10. Branson HE, Katz K, Marble R, et al. 1983. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet, 2:1165-8.
11. Broekmans AW, Bertina RM, Loeliger EA et al. 1983. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost, 49:244.
12. Brueckmann M, Horn S, Lang S, et al. 2005. Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. Thromb Haemost, 93:743-50.
13. Clarke RC, Johnston JR, Mayne EE. 2000. Meningococcal septicaemia: treatment with protein C concentrate. Intensive Care Med, 26:471-3.
14. Conard J, Bauer KA, Gruber A, et al. 1993. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood, 82(4):1159-64.
15. Dahlbäck B, Carlsson M, Svensson PJ. 1993. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA, 90:1004.
16. Dahlbäck B, Stenflo J. 1994. The protein C anticoagulant system. In The Molecular Basis of Blood Diseases. Philadelphia:W.B. Saunders Company. p 599.
17. De Fouw NJ, de Jong YF, Haverkate F, et al. 1988. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor - no evidence for a cofactor role of protein S. Thromb Haemost, 60:328-33.
18. De Kleijn ED, de Groot R, Hack CE, et al. 2003. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, doubleblinded, placebo-controlled, dose-finding study. Crit Care Med, 31:1839-47.
19. De Stefano V, Mastrangelo S, Schwarz HP, et al. 1993. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost, 70:247-9.
20. Dreyfus M, Magny JF, Bridey F, et al. 1991. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med, 325:1565-8.
21. Dreyfus M, Masterson M, David M, et al. 1995. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost, 21:371-81.
22. Dreyfus M, Ladouzi A, Chambost H, et al. 2007. Treatment of inherited protein C deficiency by replacement therapy with the French purified plasma-derived protein C concentrate (PROTEXEL). Vox Sang, 93:233-40.
23. Esmon CT. 1987. The regulation of natural anticoagulant pathways. Science, 235:1348-52.
24. Esmon CT. 1989. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem, 264:4743-6.
25. Esmon CT. 2001. Role of coagulation inhibitors in inflammation. Thromb Haemost, 86:51-6.
26. Esmon CT. 2003. The protein C pathway. Chest, 124(3 Suppl):26S-32S.
27. Esmon CT. 2006. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost, 32(Suppl 1):49-60.
28. Esmon CT, Xu J, Gu JM, et al. 1999. Endothelial Protein C Receptor. Thromb Haemost, 82:251-8.
29. Ettingshausen CE, Veldman A, Beeg T, et al. 1999. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost, 25:537-41.
30. Favier R, Deschamps A, Belhocine R, et al. 1998. Simultaneous administration of antithrombin III and protein C concentrates for the treatment of a devastating coagulopathy in a child. Hematol Cell Ther, 40:67-70.
31. Feistritzer C, Riewald M. 2005. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood, 105:3178-84.
32. Flood EP, Redish MH, Bociek SJ et al. 1943. Thrombophlebitis migrans disseminata: report of a case in which gangrene of a breast occured. N J State J Med, 43:1121-4.
33. Fouassier M, Moreau D, Thiolliere F, et al. 2005. Evolution of thrombin formation and fibrinolysis markers, including thrombin-activatable fibrinolysis inhibitor, during severe meningococcemia. Pathophysiol Haemost Thromb, 34:284-7.
34. Fourrier F, Chopin C, Goudemand J, et al. 1992. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest, 101:816-23.
35. Fourrier F, Leclerc F, Aidan K, et al. 2003. Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study. Intensive Care Med, 29:1081-7.
36. Gatti L, Carnelli V, Rusconi R, et al. 2003. Heparin-induced thrombocytopenia and warfarin-induced skin necrosis in a child with severe protein C deficiency: successful treatment with dermatan sulfate and protein C concentrate. J Thromb Haemost, 1:387-8.
37. Gerson WT, Dickerman JD, Bovill EG, et al. 1993. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics, 91:418-22.
38. Goodwin TM, Gazit G, Gordon EM. 1995. Heterozygous protein C deficiency presenting as severe protein C deficiency and peripartum thrombosis: successful treatment with protein C concentrate. Obstet Gynecol, 86:662-4.
39. Greengard JS, Fisher CL, Villoutreix B, et al. 1994. Structural basis for Type I and Type II deficiencies of antithrombotic plasma protein C: Patterns revealed by three-dirnensional molecular modelling of mutations of the protease domain. Proteins, 18:367.
40. Griffin JH, Evatt B, Zimmerman TS, et al. 1981. Deficiency of protein C in congenital thrombotic disease. J Clin Invest, 68:1370-3.
41. Hattenbach LO, Beeg T, Kreuz W, et al. 1999. Ophthalmic manifestation of congenital protein C deficiency. J AAPOS, 3:188-90.
42. Joyce DE, Grinnell BW. 2002. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med, 30(5 Suppl): S288-93.
43. Kelly JG, O'Malley K. 1979. Clinical pharmakokinetics of oral anticoagulants. Clin Pharmacokinet, 4:1-11.
44. Kreuz W, Veldman A, Escuriola-Ettingshausen C, et al. 1998. Protein-C concentrate for meningococcal purpura fulminans. Lancet, 351:986-7.
45. Lane DA, Mannucci PM, Bauer KA, et al. 1997. Inherited thrombophilia: part 2. Thromb Haemost, 76:824-34.
46. Leclerc F, Cremer R, Leteurtre S, et al. 2000. Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock. Crit Care Med, 28:1694-7.
47. Lewandowski K, Zawilska K. 1994. Protein C concentrate in the treatment of warfarin-induced skin necrosis in the protein C deficiency. Thromb Haemost, 71:395.
48. Macias WL, Nelson DR. 2004. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med, 32(Suppl):S223-8.
49. Mesters RM, Helterbrand J, Utterback BG, et al. 2000. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med, 28:2209-16.
50. Manco-Johnson M, Nuss R. 1992. Protein C concentrate prevents peripartum thrombosis. Am J Hematol, 40:69-70.
51. Manco-Johnson MJ, Knapp-Clevenger R. 2004. Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency. J Pediatr Hematol Oncol, 26:25-7.
52. Marlar RA, Montgomery RR, Broekmans AW. 1989. Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr, 114:528-34.
53. Mathias M, Khair K, Burgess C, et al. 2004. Subcutaneous administration of protein C concentrate. Pediatr Hematol Oncol, 21:551-6.
54. Minford AM, Parapia LA, Stainforth C, Lee D. 1996. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol, 93:215-6.
55. Mosnier LO, Zlokovic BV, Griffin JH. 2007. The cytoprotective protein C pathway. Blood, 109:3161-72.
56. Muller FM, Ehrenthal W, Hafner G, et al. 1996. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr, 155:20-5.
57. Mustafa S, Mannhalter C, Rintelen C, et al. 1998. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis, 9:85-9.
58. Nakayama T, Matsushita T, Hidano H, 2000. A case of purpura fulminans is caused by homozygous delta8857 mutation (protein C-nagoya) and successfully treated with activated protein C concentrate. Br J Haematol, 110:727-30.
59. Okajima K. 2001. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev, 184:258-74.
60. Pabinger I, Allaart CF, Hermans J, et al. 1992. Hereditary protein C-deficiency. Laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on Protein C and Protein S. Thromb Haemost, 68:470-4.
61. Pabinger I, Kyrle PA, Heistinger M, et al. 1994. The risk of thrombosis in asymptomatic patients with hereditary protein C or protein S deficiency. A prospective cohort study. Thromb Haemost, 71:441-5.
62. Pabinger I, Schneider B. 1996. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fuer Thrombose- und Haemostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol, 16:742-8.
63. Radosevich M, Zhoul F-L, Huart J-J, et al. 2003. Chromatographic purification and properties of a therapeutic human protein C concentrate. J Chromatography, 790:199-207.
64. Reitsma PH, Benuvdi F, Doig RG, et al. 1995. Protein C deficiency- a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientifie and Standardization Committee of the ISTH. Thromb Haemost, 73:876-89.
65. Reitsma PH. 1997. Protein C deficiency: from gene defects to disease. Thromb Haemost, 78:334-50.
66. Richards EM, Makris M, Preston FE. 1997. The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. Br J Haematol, 98:660-1.
67. Riewald M, Petrovan RJ, Donner A, et al. 2002. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 296:1880-2.
68. Rintala E, Seppala OP, Kotilainen P, et al. 1998. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med, 26:965-8.
69. Rintala E, Kauppila M, Seppala OP, et al. 2000. Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med, 28:2373-8.
70. Rivard GE, David M, Farrell C, et al. 1995. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr, 126:646-52.
71. Salonvaara M, Kuismanen K, Mononen T, et al. 2004. Diagnosis and treatment of a newborn with homozygous protein C deficiency. Acta Paediatr, 93:137-9.
72. Sanson BJ, Simioni P, Tormene D, et al. 1999. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood, 94:3702-6.
73. Sanz-Rodriguez C, Gil-Fernandez JJ, Zapater P, et al. 1999. Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate. Thromb Haemost, 81:887-90.
74. Schramm W, Spannagl M, Bauer KA, et al. 1993. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol, 129:753-6.
75. Sekiyama K, Itoh H, Sagawa N, et al. 2003. Successful management of a pregnant woman with heterozygous protein C deficiency using activated protein C concentrate. J Obstet Gynaecol Res, 29:412-5.
76. Sharon C, Tirindelli MC, Mannucci PM et al. 1986. Homozygous protein C deficiency with moderately severe clinical symptoms. Thromb Res, 41:483-8.
77. Shimamura K, Oka K, Nakazawa M, et al. 1983. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Path Lab Med, 107:543-7.
78. Smith OP, White B, Vaughan D, et al. 1997. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet, 350:1590-3.
79. Stenflo J. 1976. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem, 251:355-63.
80. Sugimoto M, Maruhashi Y, Kobayashi A, et al. 1997. Activated protein C concentrate: a new tool for the treatment of acute thromboembolism in patients with congenital protein C deficiency. Thromb Haemost, 77:1223-4.
81. Tardy-Poncet B, Rayet I, Damon G, et al. 2001. Protein C concentrates in a neonate with a cerebral venous thrombosis due to heterozygous type 1 protein C deficiency. Thromb Haemost, 85:1118-9.
82. Toupance O, Nguyen P, Brandt B, et al. 1994. Prevention of vascular thrombosis by human purified protein C concentrate in a patient with familial PC deficiency undergoing renal transplantation. Transpl Int, 7:144-5.
83. Vaccarella G, Pelella R. 2003. Replacement treatment with protein C in an 18-year-old man with meningococcal sepsis and purpura fulminans. Minerva Anestesiol, 69:693-5.
84. Van de Wouwer M, Collen D, Conway EM. 2004. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol, 24:1374-83.
85. Vukovich T, Auberger K, Weil J, et al. 1988. Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S. Br J Haematol, 70:435-40.
86. White B, Schmidt M, Murphy C, et al. 2000a. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNFalpha) production in the THP-1 monocytic cell line. Br J Haemato, 110:130-4.
87. White B, Livingstone W, Murphy C, et al. 2000b. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood, 96:3719-24.
88. Yan SB, Helterbrand JD, Hartman DL, et al. 2001. Low levels of protein C are associated with poor outcome in severe sepsis. Chest, 120:915-22.
89. Ye X, Fukudome K, Tsuneyoshi N, et al. 1999. The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries. Biochem Biophys Res Commun, 259:671-7.